Clinical Trial: Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional




Official Title: A Randomized, Vehicle Controlled, Active Comparator, Parallel Group Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Topical LFX453 Formulations in Patients With Actinic

Brief Summary: This is a randomized, vehicle controlled, active comparator, parallel group, study with a total duration of 24 weeks including screening and follow-up. Study drug is applied topically for 2 cycles of 4 week treatment, separated by 4 weeks off-treatment. Assessors of study endpoints are blinded to treatment allocation.